News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Two New Appointments at Meditor Pharmaceuticals Ltd.


5/13/2008 11:00:48 AM

REHOVOT, Israel, May 12 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today the appointment of Prof. Arie Schachner to serve as a Senior Medical Advisor to the company.

Dr. Schachner has been a member of Meditor's Scientific Advisory Board since 2001 and will now take a more active role in the Clinical Development program.

Prof. Schachner was the founder and Head of the Cardiac Surgery Department at Wolfson Medical Center and Tel Aviv University Sackler Medical School. He is an opinion leader in the Cardiac Surgery area, he is a distinguished member of several professional societies and has many publications in this field. Prof. Schachner will collaborate with recently appointed CEO, Dr. Adrian Harel, in the ongoing Phase II Clinical trial on Hypotension in patients undergoing Cardio Artery Bypass Graft (CABG) patients and in designing future clinical trials.

Dr. Adrian Harel joined Meditor in January 2008. He combines a broad scientific education with extensive industry experience. He holds a Ph.D. in Neurobiology, from the Weizmann Institute of Science, and was a postdoctoral at Washington University. Dr. Harel has many years of experience in the pharmaceutical and biotech industry. Dr. Harel has extensive Drug research & development know-how and GMP production and manufacturing knowledge.

About Meditor Pharmaceuticals: Meditor Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to the development and commercialization of proprietary products for the therapeutic management of acute and chronic hypotension and hypotension-related disorders. The lead development compound is a unique low molecular weight S-Alkylisothiouronium derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension. The clinical development program is focused on the development of lead compound MTR104 for the treatment of three main medical targets: MTR107 (i.v. formulation) for Intradialytic Hypotension, MTR106 (immediate release oral tablet formulation) for Migraine, and MTR105 (i.v. formulation) for the treatment of hypotension associated with cardiac surgery. Meditor's patent portfolio provides the company with a strong proprietary position in the U.S. and worldwide. For more information on the company and its drug development activities, please visit http://www.meditorpharma.com

For all inquiries please contact Mr. Rafi Barkan, Chairman at +972 8 930 3307 or Dr. Adrian Harel, CEO at +972 8 930 3305.

CONTACT: Mr. Rafi Barkan, Chairman, +972 8 930 3307; or Dr. Adrian Harel,
CEO, +972 8 930 3305, both of Meditor Pharmaceuticals Ltd.

Web site: http://www.meditorpharma.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES